Bay Area Chromatin and Epigenomics (BACE) Virtual Lunch & Learn

Reveal the power of the 6-base genome – introducing duet multiomics solution evoC Join us for a lively discussion where Tom Charlesworth, Ph.D., biomodal, will present a talk on using simultaneous genetic and epigenetic information from the 6-base genome to predict gene expression, chromatin accessibility and enhancer status. Click here to attend virtually.
17 April 2024
to 17 April 2024
12:00 pm
to 1:00 pm
PST
Online

About the event

The Bay Area Chromatin and Epigenomics Group (BACE) is a forum for people passionate or curious about chromatin and epigenomics.

BACE explores trends in genomics, epigenomics, and biotechnology by bringing together diverse professionals in theme-driven events.

To stay up to date on their upcoming events, please visit their page on Meetup.

Presenting at the event

Using simultaneous genetic and epigenetic information from the 6-base genome to predict gene expression, chromatin accessibility and enhancer status

Tom Charlesworth, PhD

Director, Market Strategy and Corporate Development

biomodal

12:00

Using a new sequencing technology, duet evoC, we are able to deconvolute A,T,C,G, 5-mC and 5-hmC simultaneously from the same DNA molecule in a single experiment. Using a mouse embryonic stem cell-line, ES-E14TG2A, we mapped for the first time a comprehensive reading of the genome and epigenome at high depth. We show how this 6-base genome combined with novel, memory efficient, software tools can be used to predict gene expression, chromatin accessibility and the status of gene regulatory elements.

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Attending from biomodal

Chad Geringer
Director of Sales and Business Development for North America

Register now

BACE 17Apr24

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

Cambridge Epigenetix is now biomodal